BIOXYTRAN, INC. 2025 Annual Report: Key Highlights and Investor Insights

Introduction

BIOXYTRAN, INC. (OTCQB: BIXT), a biopharmaceutical company headquartered in Needham, Massachusetts, has filed its Annual Report on Form 10-K for the year ended December 31, 2025. The following article provides an in-depth analysis of key disclosures, potential catalysts, and essential information for investors and shareholders.

1. Company Snapshot

• Business: BIOXYTRAN, INC. operates in the pharmaceutical preparations sector, focusing on novel drug candidates and dietary supplements.
• Common Stock: \$0.001 par value per share, trading on the OTCQB under the symbol “BIXT”.
• Shares Outstanding: As of April 15, 2026, the company reported 113,361,886 shares of common stock outstanding.
• Fiscal Year End: December 31.

2. Key Risk Factors and Forward-Looking Statements

The report contains several forward-looking statements about the company’s prospects, strategy, and potential risks. Investors should note the following critical risk factors highlighted by management:

• Losses Expected to Continue: The company expects to incur losses for the foreseeable future and may never achieve or maintain profitability.
• Limited Operating History: BIOXYTRAN’s limited operating history makes it difficult to evaluate its current business and future prospects.
• Financing Concerns: The company will require additional financing to implement its business plan. There is no guarantee financing will be available or offered on favorable terms. Future capital raises may cause dilution or require relinquishing rights to drug candidates and supplements.
• Novel, Unproven Technologies: The company’s products are based on new and unproven technologies, increasing the risk profile for investors.
• Lengthy and Expensive Drug Development: The process for developing clinical drug candidates is lengthy, costly, and comes with uncertainties and possible delays.
• Commercialization Risks: There is no assurance that the company will be able to commercialize its drug candidates.
• Regulatory Approvals Needed: Regulatory approvals are required to bring products to market, and these may be difficult or impossible to obtain.
• Intellectual Property: The company’s competitive position depends on its ability to protect its intellectual property.
• Intense Competition: The pharmaceutical market is rapidly changing and highly competitive, with new drugs or treatments potentially outpacing BIOXYTRAN’s offerings.
• Dependence on Key Personnel: Retaining and attracting qualified management and scientific personnel is critical to the company’s success. Loss of key personnel could materially and adversely affect operations.

3. Capital Structure & Shareholder Information

• Security Registration: The company’s common stock is registered under Section 12(g) of the Exchange Act; there are no securities registered under Section 12(b).
• Non-Accelerated Filer & Smaller Reporting Company: BIOXYTRAN is a non-accelerated filer and a smaller reporting company, which subjects it to less stringent SEC reporting requirements.
• Not a Shell Company: The company has indicated it is not a shell company, meaning it has substantive operations.

4. Recent Developments & Corporate Actions

• Share Issuance and Structure: The company’s filings indicate a series of share issuances, including:
  • Shares issued for services, debt conversion (including affiliates and management), warrant exercises, and private placements.
  • Acquisition transactions involving subsidiary NDPD Pharma Inc., with business combination entries in the filings.
  • Multiple equity instruments (options, warrants, preferred stock) with associated share-based compensation arrangements.
• Potential Dilution: The numerous referenced share issuances and conversions indicate ongoing dilution risks, which may impact the value of existing shares.

5. Financial Reporting and Controls

• Internal Controls: The company has not filed a report on, or attestation to, management’s assessment of the effectiveness of its internal controls over financial reporting by its independent auditor, as permitted for smaller reporting companies.
• No Restatement Required: The financial statements included in the filing do not reflect the correction of a material error to prior statements, and no recovery of incentive compensation is required for executive officers.

6. Corporate Governance & Compliance

• SEC Reporting: BIOXYTRAN is up to date with all required SEC filings and has submitted all Interactive Data Files (XBRL) as mandated.
• Emerging Growth Company: The company has not elected emerging growth company status.

7. Potential Catalysts That Could Affect Share Price

• Ongoing Capital Needs and Dilution: The company’s need for future financings, combined with ongoing share issuances for services, debt conversion, and private placements, could significantly impact share price and shareholder value.
• Regulatory and Development Milestones: Any advancement or setbacks in the regulatory approval process for its drug candidates could materially move the stock.
• Business Combinations and Acquisitions: The acquisition of NDPD Pharma Inc. and integration of assets, including patents, could present upside or integration risks.

Conclusion

Investor Takeaway: BIOXYTRAN, INC. remains an early-stage, high-risk biopharmaceutical company with ongoing operating losses, significant dilution risk, and various regulatory and commercialization hurdles ahead. Investors should closely monitor future financings, clinical and regulatory milestones, and further disclosures regarding acquisitions and intellectual property developments, as these could all have a substantial impact on the company’s valuation and share price.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. Investors should read the full SEC filings and consult with their financial advisor before making investment decisions. All forward-looking statements are subject to risks and uncertainties, and actual results may differ materially from those expressed or implied herein.

View BIOXYTRAN, INC Historical chart here